Levee Medical Announces Completion of Patient Accrual in ARID II Pivotal Trial Evaluating the Voro® Urologic Scaffold

Durham, NC – April 24, 2025 – Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced the enrollment of the first patient in its landmark ARID II pivotal trial. This marks a significant milestone in the company’s mission to advance the treatment of post-prostatectomy stress urinary incontinence with the Voro® Urologic Scaffold. The post Levee Medical Announces Completion of Patient Accrual in ARID II Pivotal Trial Evaluating the Voro® Urologic Scaffold appeared first on Levee Medical .